Impact BioMedical Inc. to Present at The Microcap Conference
HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Mr. Heuszel will deliver a corporate presentation and engage in one-on-one meetings with investors to discuss the company's recent developments, growth strategy, and investment opportunities.
1/23/25 4:30:35 PM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future. Dear Impact Biomedical Inc. (IBO) Shareholders, We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your
11/19/24 8:00:00 AM ET
$IBO
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our w
10/7/24 8:30:00 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care

SEC Form EFFECT filed by IBO (Listing Market - NYSE Amex Network B F)

Chat with this insight

Recent Analyst Ratings for
$IBO

$IBO
Press Releases

Fastest customizable press release news feed in the world

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

$IBO
SEC Filings

Impact BioMedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Impact BioMedical Inc.

SEC Form 10-Q filed by Impact BioMedical Inc.

$IBO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

$IBO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

SEC Form EFFECT filed by IBO (Listing Market - NYSE Amex Network B F)

Chat with this insight

Recent Analyst Ratings for $IBO

$IBO Press Releases

Fastest customizable press release news feed in the world

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

$IBO SEC Filings

Impact BioMedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Impact BioMedical Inc.

SEC Form 10-Q filed by Impact BioMedical Inc.

$IBO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

$IBO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

Recent Analyst Ratings for
$IBO

$IBO
Press Releases

$IBO
SEC Filings

$IBO
Insider Purchases

$IBO
Insider Trading